IMRN News and Press, Immuron Limited From 10/08/25

Key Points Immuron submits Investigational new drug (IND) application to FDA for clinical development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI) Previous clinical trial data on IMM-529 provides support for continue...

McCormick & Company Incorporated (MKC.V) is expected to report for Q3 2025 McCormick & Company Incorporated (MKC) is expected to report $0.81 for Q3 2025 Immuron Limited (IMRN) is expected to report for Q4 2025 TAAT Global Alternatives Inc. (TOBAF) is expected to report for qu...

2025-10-06 18:43:21 ET Immuron Limited (IMRN) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 2.06%. The average open to low on the day of earnings was -3.28%. The average open to close ...

2025-10-06 18:38:22 ET Immuron Limited (IMRN) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in IMRN stock price following earnings has averaged ±3.09% , with a median of 2.94%. The ...

Highlights: US Tariffs: Immuron does not anticipate any material impact from the recently announced US tariffs on pharmaceutical products Travelan ® Clinical Study: Topline results from the Travelan ® clinical study conducted by Uniformed Services Univers...

MELBOURNE, Australia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) advises it has entered into a partnership with InvestorHub, a direct-to-investor engagement software company that provides public companies the digital capabilities to build direct and interactive rel...

Sales Highlights (unaudited): MELBOURNE, Australia, July 17, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce continued sales growth (unaudited) of Travelan ® , an over...

Highlights: Immuron on track to exceed A$7 million in Sales this financial year Uniformed Services University anticipates topline results of Travelan ® clinical study in October 2025 Immuron anticipates IMM-529 (Clostridiodes difficile infection) IND submissio...

2025-05-15 14:30:46 ET NanoVibronix Tanks 63% on Dilutive Offering Announcement NanoVibronix Inc. ( NAOV ) plummeted over 63%, dragging down the PRISM Emerging Healthcare Index , after announcing a public offering of Series G Convertible Preferred Stock and accompanying warr...

2025-04-11 03:35:14 ET More on Immuron Seeking Alpha’s Quant Rating on Immuron Historical earnings data for Immuron Financial information for Immuron Read the full article on Seeking Alpha For further details see: Immuron exceeds AUD$5 mill...